Summary
Purpose: To determine whether a lower dose of hyperfractionated whole brain radiation reduces central nervous system morbidity without compromising survival for primary CNS lymphoma (PCNSL) patients receiving combined modality treatment.
Materials and Methods: One hundred and two patients received a course of pre-radiation chemotherapy, followed by whole brain radiation, followed by cytosine-arabinoside. Initial radiation dose was 45 Gy/25 fractions (RT) then the study was amended to reduce this dose for complete responders to induction chemotherapy to 36 Gy/30 fractions/3 weeks (HFX). Eighty-two patients received radiotherapy and were evaluable for toxicity analysis (66 RT patients and 16 HFX patients). MMSE scores and survival for the 40 patients who received radiotherapy after complete response to chemotherapy (27 RT and 13 HFX) were compared. There were no notable differences in pre-treatment patient characteristics between the RT and HFX groups.
Results: Neurotoxicity: By 4 years, there were 8/82 (10%) grade 5 neurotoxicities which included 2/16 (13%) grade 5 encephalopathies and 0/27 in the RT group of complete responders to chemotherapy. Survival: There was no statistically significant difference in overall or progression-free survival (PFS) between the chemotherapy-complete responders who received RT and HFX. Cognitive function testing: MMSE scores improved at 8 months across both treatment groups. Analysis of the area under the MMSE curve at 8 months showed no statistically significant difference between RT and HFX groups (P=0.81). Leukoencephalopathy occurred later in the HFX group than in the RT patients.
Conclusion: Although the HFX schedule represented a 25% reduction in biologically effective tumor dose in comparison, PFS and overall survival were not significantly affected. The HFX regimen delayed but did not eliminate severe neurotoxicity from chemoradiation in PCNSL patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
DF Nelson KL Martz H. Bonner et al. (1992) ArticleTitleNon-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315 Int J Radiat Oncol Biol Phys 23 9–17 Occurrence Handle1572835
C Schultz C Scott W. Sherman et al. (1996) ArticleTitlePre-irradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group protocol 88-06 J Clin Oncol 14 556–564 Occurrence Handle8636771
LM Angelis ParticleDe J Yaholom HT Thaler U. Kher (1992) ArticleTitleCombined modality therapy for primary CNS lymphoma J Clin Oncol 10 635–643 Occurrence Handle1548527
BP ONeill JR OFallon JD Earle JP Colgan L Brown R. Krigel (1995) ArticleTitlePrimary central nervous system lymphoma non-Hodgkin’s lymphoma. Survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 33 663–673 Occurrence Handle10.1016/0360-3016(95)00207-F Occurrence Handle7558957
J Glass ML Gruber L Cher FH. Hochberg (1994) ArticleTitlePre-irradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome J Neurosurg 81 188–195 Occurrence Handle8027800
JD Kalbfliesch R. Prentice (1990) The Statistical Analysis of Failure Time Data John Wiley New York 167–169
Gray RJ. A class of K-Sample tests comparing the cumulative incidence of a competing risk. J Ann Stat 16: 1141–1154
EL Kaplan P. Meier (1958) ArticleTitleNonparametric estimation from incomplete observations J Am Stat Assoc 53 457–481
N. Mantel (1966) ArticleTitleEvaluation of survival data and two new rank order statistics arising in its consideration Cancer Chem Rep 50 163–170
DR. Cox (1972) ArticleTitleRegression models and life-tables J Roy Stat Soc [B] 34 187–220
L Deangelis W Sieferheld S Schold B Fisher C. Schultz (2002) ArticleTitleCombination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group 9310 J Clin Oncol 20 IssueID24 4643–4648
HD Thames LJ Peters HR Withers GH. Fletcher (1983) ArticleTitleAccelerated fractionation: rationales for several treatments per day Int J Radiat Oncol Biol Phys 9 IssueID2 127–138
JF. Fowler (1984) ArticleTitleReview: total doses in fractionated radiotherapy – implications of new radiobiological data Int J Radiat Biol Relat Stud Phys Chem Med 46 IssueID2 103–120 Occurrence Handle6381354
RG. Dale (1989) ArticleTitleTime-dependent tumor repopulation factors in linear-quadratic equations-implications for treatment strategies Radiother Oncol 15 IssueID4 371–381 Occurrence Handle10.1016/0167-8140(89)90084-4 Occurrence Handle2798939
E Bessell A Lopez-Gullermo S Villo E Verger B Norndeder J Petit P. Byrne et al. (2002) ArticleTitleImportance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments J Clin Oncol 20 IssueID1 231–236 Occurrence Handle10.1200/JCO.20.1.231 Occurrence Handle11773174
LM Deangelis A. Hormigo (2004) ArticleTitleTreatment of primary central nervous system lymphoma Semin Oncol 31 IssueID5 684–692 Occurrence Handle15497122
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented at the American Society of Radiation Oncology, October 2001, San Francisco, California.
Rights and permissions
About this article
Cite this article
Fisher, B., Seiferheld, W., Schultz, C. et al. Secondary Analysis of Radiation Therapy Oncology Group study (RTOG) 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma. J Neurooncol 74, 201–205 (2005). https://doi.org/10.1007/s11060-004-6596-9
Issue Date:
DOI: https://doi.org/10.1007/s11060-004-6596-9